Previously we demonstrated that recombinant murine
interleukin-12 (rmIL-12) administration can promote a primary Th1 response while suppressing the Th2 response in mice primed with 2,4, 6-trinitrophenyl-keyhole limpet
hemocyanin (
TNP-KLH). The present studies examined the capacity of rmIL-12 to drive a Th1 response to
TNP-KLH in the presence of an ongoing Th2-mediated disease. To establish a distinct Th2 response, we used a murine model of
leishmaniasis. Susceptible BALB/c mice produce a strong Th2 response when infected with Leishmania major and develop progressive visceral disease. On day 26 postinfection, when
leishmaniasis was well established, groups of mice were immunized with
TNP-KLH in the presence or absence of exogenous rmIL-12. Even in the presence of overt
infection, TNP-KLH-plus-rmIL-12-immunized mice were still capable of generating KLH-specific
gamma interferon (IFN-gamma) as well as corresponding TNP-specific
immunoglobulin G2a (
IgG2a) titers. In addition, the KLH-specific
IL-4 was suppressed in infected mice immunized with rmIL-12. However, parasite-specific
IL-4 and
IgG1 production with a lack of parasite-specific IFN-gamma secretion were maintained in all infected groups of mice including those immunized with rmIL-12. These data show that despite the ongoing
infection-driven Th2 response, rmIL-12 was capable of generating an
antigen-specific Th1 response to an independent immunogen. Moreover, rmIL-12 administered with
TNP-KLH late in
infection did not alter the parasite-specific
cytokine or antibody responses.